Original language | English (US) |
---|---|
Pages (from-to) | 811-814 |
Number of pages | 4 |
Journal | Leukemia |
Volume | 33 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2019 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Comparative analysis of staging systems in AL amyloidosis. / Muchtar, Eli; Therneau, Terry M.; Larson, Dirk R.; Gertz, Morie A.; Lacy, Martha Q.; Buadi, Francis K.; Dingli, David; Hayman, Suzanne R.; Kapoor, Prashant; Gonsalves, Wilson; Kourelis, Taxiarchis V.; Warsame, Rahma; Fonder, Amie; Hobbs, Miriam; Hwa, Yi Lisa; Leung, Nelson; Russell, Stephen; Lust, John A.; Lin, Yi; Go, Ronald S.; Zeldenrust, Steven; Kyle, Robert A.; Rajkumar, S. Vincent; Kumar, Shaji K.; Dispenzieri, Angela.
In: Leukemia, Vol. 33, No. 3, 01.03.2019, p. 811-814.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Comparative analysis of staging systems in AL amyloidosis
AU - Muchtar, Eli
AU - Therneau, Terry M.
AU - Larson, Dirk R.
AU - Gertz, Morie A.
AU - Lacy, Martha Q.
AU - Buadi, Francis K.
AU - Dingli, David
AU - Hayman, Suzanne R.
AU - Kapoor, Prashant
AU - Gonsalves, Wilson
AU - Kourelis, Taxiarchis V.
AU - Warsame, Rahma
AU - Fonder, Amie
AU - Hobbs, Miriam
AU - Hwa, Yi Lisa
AU - Leung, Nelson
AU - Russell, Stephen
AU - Lust, John A.
AU - Lin, Yi
AU - Go, Ronald S.
AU - Zeldenrust, Steven
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
AU - Kumar, Shaji K.
AU - Dispenzieri, Angela
N1 - Funding Information: Acknowledgements The study was supported by the Jabbs Foundation (Birmingham, United Kingdom), the Henry J. Predolin Foundation (USA), and National Institutes of Health National Cancer Institute grant P50 CA186781. Funding Information: Conflict of interest MAG: Consultancy (Milleniu) and honoraria (Cel-gene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis); MQL: Research funding (Celgene); DD: Research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); PK: Research funding (Takeda, Celgene, and Amgen); SKK: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS) and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS); AD: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). The remaining authors declare that they have no conflict of interest.
PY - 2019/3/1
Y1 - 2019/3/1
UR - http://www.scopus.com/inward/record.url?scp=85060567465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060567465&partnerID=8YFLogxK
U2 - 10.1038/s41375-018-0370-z
DO - 10.1038/s41375-018-0370-z
M3 - Letter
C2 - 30675009
AN - SCOPUS:85060567465
VL - 33
SP - 811
EP - 814
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 3
ER -